A5001540331- Colorectal Cancer Surgical Treatments
- Genetic factors in colorectal cancer
- Colorectal Cancer Screening and Detection
- Colorectal and Anal Carcinomas
- Lipoproteins and Cardiovascular Health
- Colorectal Cancer Treatments and Studies
- COVID-19 and healthcare impacts
- Multiple and Secondary Primary Cancers
- Cancer Genomics and Diagnostics
- Inflammatory Biomarkers in Disease Prognosis
- Cancer, Lipids, and Metabolism
Hospital Universitario La Paz
2022-2025
Abstract Background Stage II and III colorectal cancer (CRC) poses a significant challenge due to rising global incidence mortality rates. Despite advancements in screening treatment, there’s pressing need for reliable prognostic biomarkers. Tumor budding emerges as promising marker associated with poor prognosis higher recurrence. However, its incorporation into clinical guidelines differs when considering adjuvant treatment. This study assesses tumor budding’s value recurrence stage CRC,...
Background: The prognosis of patients with stage II and III colon cancer is heterogeneous. Clinical pathological characteristics, such as tumor budding, may help to further refine the recurrence risk. Methods: We included all localized at Hospital Universitario La Paz from October 2016 2021. built a prognostic score for in training cohort based on multivariate cox regression analysis categorized into two risk groups. Results: A total 440 were cohort. After median follow-up 45 months, 81...
The rising incidence of colorectal cancer (CRC) among young patients is alarming. We aim to characterize the clinico-pathological features and outcomes with early-onset CRC (EOCRC), as well impacts COVID-19 pandemic.We included all pathologically confirmed diagnoses at Hospital Universitario La Paz from October 2016 December 2021. EOCRC cut-off age was 50 years old.A total 1475 diagnosed were included, eighty (5.4%) whom had EOCRC. Significant differences found between later-onset regarding...
247 Background: Tumor budding has recently been recognized as one important prognostic factor for recurrence in patients with localized colon cancer. Nevertheless, not all guidelines consider tumor the decision-making process selecting adjuvant chemotherapy. We aim to assess value of a cohort stage II and III Methods: included pathologically confirmed diagnosis cancer at Hospital Universitario La Paz assessment available, from October 2016 August 2021. was reported following recommendations...
Background: MUTYH has been implicated in hereditary colonic polyposis and colorectal carcinoma. However, there are conflicting data refgarding its relationship to breast cancer. Therefore, we aimed assess if mutations contribute cancer susceptibility. Methods: We retrospectively reviewed 3598 patients evaluated from June 2018 2023 at the Hereditary Cancer Unit of La Paz University Hospital, focusing on those with detected variants. Results: Variants were 56 (1.6%, 95%CI: 1.2–2.0). Of 766...
215 Background: The prognosis of stage II and III colon cancer is heterogeneous current staging system do not accurately predict recurrence. We previously reported a score that was able to select subgroup patient with excellent ( https://doi.org/10.1016/j.annonc.2022.04.177 ). Here we present long-term follow up the experimental cohort results validation cohort. Methods: included patients pathologically confirmed diagnosis at Hospital Universitario La Paz. from October 2016 September 2020....
15 Background: Although we seem to be recovering from COVID-19, are now facing the long-term consequence of pandemic on vulnerable subgroup patients such as with early-onset colorectal cancer (EOCRC). We aim study how COVID-19 affected diagnosis and clinic-pathological characteristics, treatment outcomes EOCRC. Methods: This is an observational retrospective including EOCRC diagnosed between September 2016 August 2021 at Hospital Universitario La Paz, Madrid, Spain. Two cohorts were...